目的通过检测NOD样受体蛋白3(NLRP3)/半胱氨酸天冬氨酸蛋白水解酶-1(Caspase-1)/消皮素D(GSDMD)通路,探讨阿霉素纳米凝胶载药(Nanogel drug loading,NG)对H22肝癌荷瘤小鼠的作用机制。方法将H22肝癌细胞珠每只1.25×106个/100μl接...目的通过检测NOD样受体蛋白3(NLRP3)/半胱氨酸天冬氨酸蛋白水解酶-1(Caspase-1)/消皮素D(GSDMD)通路,探讨阿霉素纳米凝胶载药(Nanogel drug loading,NG)对H22肝癌荷瘤小鼠的作用机制。方法将H22肝癌细胞珠每只1.25×106个/100μl接种于Balb/c小鼠右前肢腋窝皮下,待肿瘤体积至50~60mm3时,将40只Balb/c小鼠随机分为5组(n=8),分别为肿瘤对照组、阿霉素3mg组(DOX-3.0)、阿霉素6mg组(DOX-6.0)、阿霉素纳米凝胶载药3mg组(NG/DOX-3.0)和阿霉素纳米凝胶载药6mg组(NG/DOX-6.0)。各组均采用尾静脉注射给药治疗,分别给予生理盐水(5ml/kg)、DOX(3mg/kg)、DOX(6mg/kg)、NG/DOX(3mg/kg)和NG/DOX(6mg/kg),1次/3d,给药4次,于给药结束第3d处死动物取材。通过苏木精-伊红(hematoxylin-eosin,HE)染色,观察肿瘤生长情况和坏死面积;采用免疫组织化学染色检测NLRP3/Caspase-1/GSDMD凋亡基因的表达情况。结果HE染色与肿瘤对照组比较,各治疗组肿瘤生长状态较差,且DOX-3.0、NG/DOX-3.0、DOX-6.0、NG/DOX-6.0肿瘤坏死面积百分率依次增大,组间差异均有统计学意义(P<0.05);与肿瘤对照组比较,DOX-3.0、NG/DOX-3.0、DOX-6.0、NG/DOX-6.0组肿瘤组织中NLRP3、Caspase-1、GSDMD的蛋白阳性表达水平依次减弱,组间差异均有统计学意义(P<0.05),纳米凝胶载药组作用优于单纯阿霉素给药组。结论纳米凝胶载药组治疗H22肝癌的作用优于阿霉素单独用药,它能通过下调NLRP3/Caspase-1/GSDMD通路,有效抑制肿瘤生长、降低药物使用剂量及提高抗癌效果,具有良好发展前景,其作用机制有待于进一步探讨。展开更多
BACKGROUND Macrophages are central to the orchestration of immune responses,inflammatory processes,and the pathogenesis of diabetic complications.The dynamic polarization of macrophages into M1 and M2 phenotypes criti...BACKGROUND Macrophages are central to the orchestration of immune responses,inflammatory processes,and the pathogenesis of diabetic complications.The dynamic polarization of macrophages into M1 and M2 phenotypes critically modulates inflammation and contributes to the progression of diabetic nephropathy.Sodiumglucose cotransporter 2 inhibitors such as dapagliflozin,which are acclaimed for their efficacy in diabetes management,may influence macrophage polarization,thereby ameliorating diabetic nephropathy.This investigation delves into these mechanistic pathways,aiming to elucidate novel therapeutic strategies for diabetes.AIM To investigate the inhibitory effect of dapagliflozin on macrophage M1 polarization and apoptosis and to explore its mechanism of action.METHODS We established a murine model of type 2 diabetes mellitus and harvested peritoneal macrophages following treatment with dapagliflozin.Concurrently,the human monocyte cell line cells were used for in vitro studies.Macrophage viability was assessed in a cell counting kit 8 assay,whereas apoptosis was evaluated by Annexin V/propidium iodide staining.Protein expression was examined through western blotting,and the expression levels of macrophage M1 surface immunosorbent assay,and quantitative real-time polymerase chain reaction analyses.RESULTS Dapagliflozin attenuated M1 macrophage polarization and mitigated apoptosis in the abdominal macrophages of diabetic mice,evidenced by the downregulation of proapoptotic genes(Caspase 3),inflammatory cytokines[interleukin(IL)-6,tumor necrosis factor-α,and IL-1β],and M1 surface markers(inducible nitric oxide synthase,and cluster of differentiation 86),as well as the upregulation of the antiapoptotic gene BCL2.Moreover,dapagliflozin suppressed the expression of proteins associated with the phosphoinositide 3-kinase(PI3K)/protein kinase B(AKT)signaling pathway(PI3K,AKT,phosphorylated protein kinase B).These observations were corroborated in vitro,where we found that the modulatory effects of dapagliflozin were abrogated by 740Y-P,an activator of the PI3K/AKT signaling pathway.CONCLUSION Dapagliflozin attenuates the polarization of macrophages toward the M1 phenotype,thereby mitigating inflammation and promoting macrophage apoptosis.These effects are likely mediated through the inhibition of the PI3K/AKT signaling pathway.展开更多
The nucleotide-binding domain,leucine-rich repeat,and pyrin domain-containing protein 3(NLRP3)inflammasome is a critical modulator in inflammatory disease.Activation and mutation of NLRP3 can cause severe inflammation...The nucleotide-binding domain,leucine-rich repeat,and pyrin domain-containing protein 3(NLRP3)inflammasome is a critical modulator in inflammatory disease.Activation and mutation of NLRP3 can cause severe inflammation in diseases such as chronic infantile neurologic cutaneous and articular syndrome,Muckle-Wells syndrome,and familial cold autoinflammatory syndrome 1.To date,a great effort has been made to decode the underlying mechanisms of NLRP3 activation.The priming and activation of NLRP3 drive the maturation and release of active interleukin(IL)-18 and IL-1βto cause inflammation and pyroptosis,which can significantly trigger many diseases including inflammatory diseases,immune disorders,metabolic diseases,and neurodegenerative diseases.The investigation of NLRP3 as a therapeutic target for disease treatment is a hot topic in both preclinical studies and clinical trials.Developing potent NLRP3 inhibitors and downstream IL-1 inhibitors attracts wide-spectrum attention in both research and pharmaceutical fields.In this minireview,we first updated the molecular mechanisms involved in NLRP3 inflammasome activation and the associated downstream signaling pathways.We then reviewed the molecular and cellular pathways of NLRP3 in many diseases,including obesity,diabetes,and other metabolic diseases.In addition,we briefly reviewed the roles of NLRP3 in cancer growth and relative immune checkpoint therapy.Finally,clinical trials with treatments targeting NLRP3 and its downstream signaling pathways were summarized.展开更多
BACKGROUND Diabetic macular edema(DME)is the most common cause of vision loss in people with diabetes.Tight junction disruption of the retinal pigment epithelium(RPE)cells has been reported to induce DME development.S...BACKGROUND Diabetic macular edema(DME)is the most common cause of vision loss in people with diabetes.Tight junction disruption of the retinal pigment epithelium(RPE)cells has been reported to induce DME development.SMAD-specific E3 ubiquitin protein ligase(SMURF)1 was associated with the tight junctions of cells.However,the mechanism of SMURF1 in the DME process remains unclear.AIM To investigate the role of SMURF1 in RPE cell tight junction during DME.METHODS ARPE-19 cells treated with high glucose(HG)and desferrioxamine mesylate(DFX)for establishment of the DME cell model.DME mice models were constructed by streptozotocin induction.The trans-epithelial electrical resistance and permeability of RPE cells were analyzed.The expressions of tight junction-related and autophagy-related proteins were determined.The interaction between insulin like growth factor 2 mRNA binding protein 2(IGF2BP2)and SMURF1 mRNA was verified by RNA immunoprecipitation(RIP).SMURF1 N6-methyladenosine(m6A)level was detected by methylated RIP.RESULTS SMURF1 and vascular endothelial growth factor(VEGF)were upregulated in DME.SMURF1 knockdown reduced HG/DFX-induced autophagy,which protected RPE cell tight junctions and ameliorated retinal damage in DME mice.SMURF1 activated the Wnt/β-catenin-VEGF signaling pathway by promoting WNT inhibitory factor(WIF)1 ubiquitination and degradation.IGF2BP2 upregulated SMURF1 expression in an m6A modification-dependent manner.CONCLUSION M6A-modified SMURF1 promoted WIF1 ubiquitination and degradation,which activated autophagy to inhibit RPE cell tight junctions,ultimately promoting DME progression.展开更多
目的探讨三黄连合剂通过NOD样受体蛋白3(NOD-like receptor protein domain associated protein 3,NLRP3)/凋亡相关颗粒样蛋白(apoptosis-associated speck-like protein containing a CARD,ASC)/半胱氨酸天冬氨酸蛋白酶1(cysteine aspa...目的探讨三黄连合剂通过NOD样受体蛋白3(NOD-like receptor protein domain associated protein 3,NLRP3)/凋亡相关颗粒样蛋白(apoptosis-associated speck-like protein containing a CARD,ASC)/半胱氨酸天冬氨酸蛋白酶1(cysteine aspartic acid specific protease-1,Caspase-1)通路对哮喘患儿气道炎症的作用及机制。方法选取2021年1月—2023年10月就诊的90例哮喘患儿,采用数字表法随机分为观察组与对照组,各45例。观察2组哮喘患儿不良反应、1 s用力呼气容积(forced expiratory volume in the first second,FEV_(1)%)、最大呼气流量(peak expiratory flow,PEF)、用力肺活量(forced vital capacity,FVC)、白细胞介素-1β(interleukin-1β,IL-1β)及TNF-α(tumor necrosis factor-α,TNF-α)表达水平差异。结果观察组不良反应发生率为6.66%,对照组为11.11%,差异无统计学意义(P>0.05)。观察组总有效率为95.56%,高于对照组的80.00%(P<0.05)。治疗后FEV_(1)%、PEF、FVC、哮喘控制测试表(asthma control test,ACT)评分高于对照组(P<0.05)。治疗后观察组血清IL-1β、IL-6、IL-8、IL-17、IL-18水平低于对照组(P<0.05)。治疗后观察组患儿血清NLRP3、ASC、Caspase-1、IL-1β蛋白表达水平低于对照组(P<0.05)。结论三黄连合剂治疗能减轻哮喘患儿气道炎症反应,降低炎症因子水平,改善肺功能,减轻病情,提高疗效,其可能通过NLRP3/ASC/Caspase-1通路发挥作用。展开更多
文摘目的通过检测NOD样受体蛋白3(NLRP3)/半胱氨酸天冬氨酸蛋白水解酶-1(Caspase-1)/消皮素D(GSDMD)通路,探讨阿霉素纳米凝胶载药(Nanogel drug loading,NG)对H22肝癌荷瘤小鼠的作用机制。方法将H22肝癌细胞珠每只1.25×106个/100μl接种于Balb/c小鼠右前肢腋窝皮下,待肿瘤体积至50~60mm3时,将40只Balb/c小鼠随机分为5组(n=8),分别为肿瘤对照组、阿霉素3mg组(DOX-3.0)、阿霉素6mg组(DOX-6.0)、阿霉素纳米凝胶载药3mg组(NG/DOX-3.0)和阿霉素纳米凝胶载药6mg组(NG/DOX-6.0)。各组均采用尾静脉注射给药治疗,分别给予生理盐水(5ml/kg)、DOX(3mg/kg)、DOX(6mg/kg)、NG/DOX(3mg/kg)和NG/DOX(6mg/kg),1次/3d,给药4次,于给药结束第3d处死动物取材。通过苏木精-伊红(hematoxylin-eosin,HE)染色,观察肿瘤生长情况和坏死面积;采用免疫组织化学染色检测NLRP3/Caspase-1/GSDMD凋亡基因的表达情况。结果HE染色与肿瘤对照组比较,各治疗组肿瘤生长状态较差,且DOX-3.0、NG/DOX-3.0、DOX-6.0、NG/DOX-6.0肿瘤坏死面积百分率依次增大,组间差异均有统计学意义(P<0.05);与肿瘤对照组比较,DOX-3.0、NG/DOX-3.0、DOX-6.0、NG/DOX-6.0组肿瘤组织中NLRP3、Caspase-1、GSDMD的蛋白阳性表达水平依次减弱,组间差异均有统计学意义(P<0.05),纳米凝胶载药组作用优于单纯阿霉素给药组。结论纳米凝胶载药组治疗H22肝癌的作用优于阿霉素单独用药,它能通过下调NLRP3/Caspase-1/GSDMD通路,有效抑制肿瘤生长、降低药物使用剂量及提高抗癌效果,具有良好发展前景,其作用机制有待于进一步探讨。
基金Natural Science Foundation of Anhui Province,No.2208085MH216Major Natural Science and Technology Project of Bengbu Medical College,No.2020byfy004Scientific Research Program of Anhui Provincial Health Commission,No.AHWJ2023BAc10028.
文摘BACKGROUND Macrophages are central to the orchestration of immune responses,inflammatory processes,and the pathogenesis of diabetic complications.The dynamic polarization of macrophages into M1 and M2 phenotypes critically modulates inflammation and contributes to the progression of diabetic nephropathy.Sodiumglucose cotransporter 2 inhibitors such as dapagliflozin,which are acclaimed for their efficacy in diabetes management,may influence macrophage polarization,thereby ameliorating diabetic nephropathy.This investigation delves into these mechanistic pathways,aiming to elucidate novel therapeutic strategies for diabetes.AIM To investigate the inhibitory effect of dapagliflozin on macrophage M1 polarization and apoptosis and to explore its mechanism of action.METHODS We established a murine model of type 2 diabetes mellitus and harvested peritoneal macrophages following treatment with dapagliflozin.Concurrently,the human monocyte cell line cells were used for in vitro studies.Macrophage viability was assessed in a cell counting kit 8 assay,whereas apoptosis was evaluated by Annexin V/propidium iodide staining.Protein expression was examined through western blotting,and the expression levels of macrophage M1 surface immunosorbent assay,and quantitative real-time polymerase chain reaction analyses.RESULTS Dapagliflozin attenuated M1 macrophage polarization and mitigated apoptosis in the abdominal macrophages of diabetic mice,evidenced by the downregulation of proapoptotic genes(Caspase 3),inflammatory cytokines[interleukin(IL)-6,tumor necrosis factor-α,and IL-1β],and M1 surface markers(inducible nitric oxide synthase,and cluster of differentiation 86),as well as the upregulation of the antiapoptotic gene BCL2.Moreover,dapagliflozin suppressed the expression of proteins associated with the phosphoinositide 3-kinase(PI3K)/protein kinase B(AKT)signaling pathway(PI3K,AKT,phosphorylated protein kinase B).These observations were corroborated in vitro,where we found that the modulatory effects of dapagliflozin were abrogated by 740Y-P,an activator of the PI3K/AKT signaling pathway.CONCLUSION Dapagliflozin attenuates the polarization of macrophages toward the M1 phenotype,thereby mitigating inflammation and promoting macrophage apoptosis.These effects are likely mediated through the inhibition of the PI3K/AKT signaling pathway.
文摘The nucleotide-binding domain,leucine-rich repeat,and pyrin domain-containing protein 3(NLRP3)inflammasome is a critical modulator in inflammatory disease.Activation and mutation of NLRP3 can cause severe inflammation in diseases such as chronic infantile neurologic cutaneous and articular syndrome,Muckle-Wells syndrome,and familial cold autoinflammatory syndrome 1.To date,a great effort has been made to decode the underlying mechanisms of NLRP3 activation.The priming and activation of NLRP3 drive the maturation and release of active interleukin(IL)-18 and IL-1βto cause inflammation and pyroptosis,which can significantly trigger many diseases including inflammatory diseases,immune disorders,metabolic diseases,and neurodegenerative diseases.The investigation of NLRP3 as a therapeutic target for disease treatment is a hot topic in both preclinical studies and clinical trials.Developing potent NLRP3 inhibitors and downstream IL-1 inhibitors attracts wide-spectrum attention in both research and pharmaceutical fields.In this minireview,we first updated the molecular mechanisms involved in NLRP3 inflammasome activation and the associated downstream signaling pathways.We then reviewed the molecular and cellular pathways of NLRP3 in many diseases,including obesity,diabetes,and other metabolic diseases.In addition,we briefly reviewed the roles of NLRP3 in cancer growth and relative immune checkpoint therapy.Finally,clinical trials with treatments targeting NLRP3 and its downstream signaling pathways were summarized.
基金Supported by Natural Science Foundation of Guangdong Province,No.2022A1515012346.
文摘BACKGROUND Diabetic macular edema(DME)is the most common cause of vision loss in people with diabetes.Tight junction disruption of the retinal pigment epithelium(RPE)cells has been reported to induce DME development.SMAD-specific E3 ubiquitin protein ligase(SMURF)1 was associated with the tight junctions of cells.However,the mechanism of SMURF1 in the DME process remains unclear.AIM To investigate the role of SMURF1 in RPE cell tight junction during DME.METHODS ARPE-19 cells treated with high glucose(HG)and desferrioxamine mesylate(DFX)for establishment of the DME cell model.DME mice models were constructed by streptozotocin induction.The trans-epithelial electrical resistance and permeability of RPE cells were analyzed.The expressions of tight junction-related and autophagy-related proteins were determined.The interaction between insulin like growth factor 2 mRNA binding protein 2(IGF2BP2)and SMURF1 mRNA was verified by RNA immunoprecipitation(RIP).SMURF1 N6-methyladenosine(m6A)level was detected by methylated RIP.RESULTS SMURF1 and vascular endothelial growth factor(VEGF)were upregulated in DME.SMURF1 knockdown reduced HG/DFX-induced autophagy,which protected RPE cell tight junctions and ameliorated retinal damage in DME mice.SMURF1 activated the Wnt/β-catenin-VEGF signaling pathway by promoting WNT inhibitory factor(WIF)1 ubiquitination and degradation.IGF2BP2 upregulated SMURF1 expression in an m6A modification-dependent manner.CONCLUSION M6A-modified SMURF1 promoted WIF1 ubiquitination and degradation,which activated autophagy to inhibit RPE cell tight junctions,ultimately promoting DME progression.
文摘目的探讨三黄连合剂通过NOD样受体蛋白3(NOD-like receptor protein domain associated protein 3,NLRP3)/凋亡相关颗粒样蛋白(apoptosis-associated speck-like protein containing a CARD,ASC)/半胱氨酸天冬氨酸蛋白酶1(cysteine aspartic acid specific protease-1,Caspase-1)通路对哮喘患儿气道炎症的作用及机制。方法选取2021年1月—2023年10月就诊的90例哮喘患儿,采用数字表法随机分为观察组与对照组,各45例。观察2组哮喘患儿不良反应、1 s用力呼气容积(forced expiratory volume in the first second,FEV_(1)%)、最大呼气流量(peak expiratory flow,PEF)、用力肺活量(forced vital capacity,FVC)、白细胞介素-1β(interleukin-1β,IL-1β)及TNF-α(tumor necrosis factor-α,TNF-α)表达水平差异。结果观察组不良反应发生率为6.66%,对照组为11.11%,差异无统计学意义(P>0.05)。观察组总有效率为95.56%,高于对照组的80.00%(P<0.05)。治疗后FEV_(1)%、PEF、FVC、哮喘控制测试表(asthma control test,ACT)评分高于对照组(P<0.05)。治疗后观察组血清IL-1β、IL-6、IL-8、IL-17、IL-18水平低于对照组(P<0.05)。治疗后观察组患儿血清NLRP3、ASC、Caspase-1、IL-1β蛋白表达水平低于对照组(P<0.05)。结论三黄连合剂治疗能减轻哮喘患儿气道炎症反应,降低炎症因子水平,改善肺功能,减轻病情,提高疗效,其可能通过NLRP3/ASC/Caspase-1通路发挥作用。
